Browse by author
Lookup NU author(s): Professor John IsaacsORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
During the past decade biologic therapies such as monoclonal antibodies and fusion proteins have revolutionized the management of rheumatic disease. By targeting key cytokines and immune cells biologics have provided more specific therapeutic interventions with less immunosuppression. Clinical use, however, has revealed that their theoretical simplicity hides a more complex reality. Efficacy, toxicity and even pharmacodynamic effects can deviate from those predicted, as poignantly illustrated by the catastrophic effects witnessed during the first-into-human administration of TGN1412. This review summarizes lessons gleaned from practical experience and discusses how these can inform future discovery and development of new biologic therapies for rheumatology.
Author(s): Strand V, Kimberly R, Isaacs JD
Publication type: Review
Publication status: Published
Journal: Nature Reviews Drug Discovery
Year: 2007
Volume: 6
Issue: 1
Pages: 75-92
Print publication date: 01/01/2007
ISSN (print): 1474-1776
ISSN (electronic): 1474-1784
URL: http://dx.doi.org/10.1038/nrd2196
DOI: 10.1038/nrd2196
PubMed id: 17195034
